8-K: Cullinan Therapeutics Announces Positive Initial Data for Zipalertinib in Lung Cancer Trial

Cullinan Therapeutics reports positive initial Phase 2b trial data for zipalertinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations who progressed after amivantamab treatment.

Summary

• Cullinan Therapeutics announced initial clinical data from the Phase 2b portion of the REZILIENT1 trial for zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
• The study focused on patients who had previously been treated with amivantamab.
• As of January 12, 2024, 31 patients were enrolled, with 18 evaluable for response.
• The overall response rate (ORR) was 39%, and the disease control rate (DCR) was 94%, which is similar to results seen in patients who progressed after chemotherapy alone in a previous Phase 1/2a study.
• Zipalertinib showed a manageable safety profile with no grade 4 or 5 treatment-related adverse events.
• The company is co-developing zipalertinib with Taiho Pharmaceutical Co., Ltd., and the pivotal REZILIENT1 trial is on track to complete enrollment by the end of 2024.

Sentiment

Score: 8

Explanation: The document presents positive initial data for zipalertinib, with a manageable safety profile and a clear path to potential commercialization. The partnership with Taiho also provides financial stability. The sentiment is positive, but the study is still ongoing, and there are risks associated with clinical trials and regulatory approvals.

Positives

• The 39% objective response rate for zipalertinib in patients previously treated with amivantamab is promising.
• The disease control rate of 94% indicates a high level of disease stabilization.
• The safety profile of zipalertinib is manageable, with no grade 4 or 5 adverse events reported.
• The REZILIENT1 trial is progressing as planned, with enrollment expected to complete by the end of 2024.
• The partnership with Taiho provides significant financial support and a clear path to commercialization.

Risks

• The study is still ongoing, and the results are based on a limited number of patients (18 evaluable for response).
• The duration of response and progression-free survival are not yet estimable, which makes it difficult to assess the long-term efficacy of zipalertinib.
• The company is reliant on the success of clinical trials and regulatory approvals to realize the full potential of zipalertinib.
• There are risks associated with manufacturing, supply, and distribution of the drug.
• The competitive landscape for lung cancer treatments is evolving, and there is no guarantee that zipalertinib will be successful in the market.

Future Outlook

Cullinan Therapeutics is focused on completing enrollment in the pivotal Phase 2b REZILIENT1 trial by the end of 2024 and advancing its broad development program for zipalertinib, including a randomized frontline study.

Management Comments

• Jeffrey Jones, MD, MBA, Chief Medical Officer, stated that the initial results of the Phase 2b portion of the REZILIENT1 clinical trial are encouraging, showing promising efficacy in a post-amivantamab setting.
• Management believes the data strengthens their confidence in zipalertinib's potential to address a significant unmet need for patients with NSCLC harboring EGFR exon 20 insertion mutations.

Industry Context

The announcement is significant as it provides data on the efficacy of zipalertinib in patients who have progressed after treatment with amivantamab, a recently approved first-line treatment for NSCLC with EGFR exon 20 insertion mutations. This addresses a critical unmet need in the treatment landscape.

Comparison to Industry Standards

• The 39% ORR for zipalertinib is comparable to the 41% ORR observed in the Phase 1/2a study in patients who progressed after chemotherapy alone, suggesting that zipalertinib maintains its efficacy even after amivantamab treatment.
• Other EGFR inhibitors, such as mobocertinib and poziotinib, have shown varying degrees of efficacy in this patient population, but zipalertinib's unique chemical structure and selectivity may offer a differentiated approach.
• The data suggests that zipalertinib could be a valuable option for patients who have failed other treatments, including amivantamab, which is a significant advancement in the treatment of this specific type of lung cancer.
• The company is also conducting a randomized Phase 3 study comparing zipalertinib plus chemotherapy to chemotherapy alone, which will provide further insight into its efficacy in the first-line setting. This is similar to other companies who are also testing their drugs in combination with chemotherapy.

Related Party Transactions

• Cullinan entered into a partnership with Taiho in 2022, with an upfront cash payment of $275M and additional payments totaling $130M to be made for US regulatory approvals in 1L and 2L+ NSCLC.
• Cullinan also retains a 50/50 profit share in the U.S.

Stakeholder Impact

• Shareholders: The positive clinical data and partnership with Taiho are likely to be viewed favorably by investors.
• Patients: The results suggest that zipalertinib could be a valuable treatment option for patients with NSCLC harboring EGFR exon 20 insertion mutations, particularly those who have progressed after amivantamab treatment.
• Employees: The progress of the clinical trial and the partnership with Taiho may boost employee morale and confidence in the company's future.
• Partners: The partnership with Taiho is a key factor in the development and commercialization of zipalertinib.

Next Steps

• Complete enrollment in the pivotal Phase 2b REZILIENT1 trial by the end of 2024.
• Continue the broad development program for zipalertinib, including two ongoing pivotal studies in first-line and second-line+ exon20 insertion NSCLC.
• Advance clinical trials in other patient populations, such as those with active brain metastases and uncommon EGFR mutations.
• Explore combination therapies with chemotherapy.

Key Dates

Keywords

zipalertinib, NSCLC, EGFR exon 20 insertion, amivantamab, lung cancer, clinical trial, REZILIENT1, Taiho Pharmaceutical, oncology, targeted therapy